Tumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II Study
Ajay V. Maker, Giao Q. Phan, Peter Attia et al. · Annals of Surgical Oncology · 2005
Cited by 492 works. doi:10.1245/aso.2005.03.536
Authors
- Ajay V. Maker
- Giao Q. Phan
- Peter Attia
- James Chih‐Hsin Yang
- Richard Mark Sherry
- Suzanne Louise Topalian
- Udai S. Kammula
- Richard Eldon Royal
- Leah R. Haworth
- Catherine L. Levy
- David Erwin Kleiner
- Sharon A. Mavroukakis
- Michael Jay Yellin
- Steven A. Rosenberg
References
- Enhancement of Antitumor Immunity by CTLA-4 Blockade
- Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
- CTLA-4 is a second receptor for the B cell activation antigen B7.
- Cytotoxic T Lymphocyte–Associated Antigen 4 Plays an Essential Role in the Function of Cd25+Cd4+ Regulatory Cells That Control Intestinal Inflammation
- A Cell Culture Model for T Lymphocyte Clonal Anergy
- CD28/B7 SYSTEM OF T CELL COSTIMULATION
- Immunologic Self-Tolerance Maintained by Cd25+Cd4+Regulatory T Cells Constitutively Expressing Cytotoxic T Lymphocyte–Associated Antigen 4
- Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
- Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4
- High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993